Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Haematological malignancies

3709 - Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study


11 Sep 2017


Haematological malignancies




Mariano Provencio Pulla


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


M. Provencio Pulla1, A. Santoro2, L. Mollica3, S. Leppä4, G. Follows5, G. Lenz6, W.S. Kim7, A. Nagler8, P. Panayiotidis9, J. Demeter10, M. Özcan11, M. Kosinova12, K. Bouabdallah13, F. Morschhauser14, T. Ishida15, L. Huang16, J. Garcia-Vargas17, B.H. Childs17, P.L. Zinzani18, M. Dreyling19

Author affiliations

  • 1 Servicio De Oncología Médica, Hospital Universitario Puerta de Hierro, 28222 - Madrid/ES
  • 2 Department Of Oncology And Hematology, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 3 Department Of Hematology, Hôpital Maisonneuve-Rosemont-Montreal, Montreal/CA
  • 4 Department Of Oncology, Helsinki University Central Hospital, 00029 - Helsinki/FI
  • 5 Department Of Haematology, Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital |, Cambridge/GB
  • 6 Translational Oncology, University Hospital Münster, Münster/DE
  • 7 Division Of Hematology And Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul/KR
  • 8 Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer/IL
  • 9 Molecular Hematology Laboratory, 1st Department Of Propaedeutic Medicine, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens/GR
  • 10 First Department Of Internal Medicine, Division Of Haematology, Semmelweis University, Budapest/HU
  • 11 Department Of Hematology, Ankara University School of Medicine, Ankara/TR
  • 12 Department Of Hematology, GAUZKO "Kemerovo Regional Clinical Hospital", 650066 - Kemerovo/RU
  • 13 Service D'hématologie Et De Thérapie Cellulaire, University Hospital of Bordeaux, Pessac/FR
  • 14 Department Of Hematology, CHRU - Hôpital Claude Huriez, Lille/FR
  • 15 Development Operations, Bayer SA, São Paulo/BR
  • 16 Clinical Statistics, Bayer HealthCare Pharmaceuticals USA, 07981 - Whippany/US
  • 17 Clinical Development, Bayer HealthCare Pharmaceuticals Inc., 07981 - Whippany/US
  • 18 Institute Of Hematology “l. E A. Seràgnoli”, University of Bologna, Bologna/IT
  • 19 Medizinische Klinik Und Poliklinik Iii, Klinikum der Universität München-Grosshadern, Munich/DE


Abstract 3709


Copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against PI3K-α and PI3K-δ isoforms, has recently been shown to achieve a 59% objective tumor response rate (ORR) in a phase II study in patients with relapsed or refractory (r/r) indolent B-cell lymphoma. We report here the results of subgroup analyses conducted based on demographic and baseline disease characteristics.


Patients with indolent B-cell non-Hodgkin lymphoma (4 subtypes: follicular [FL], marginal zone [MZL], small lymphocytic [SLL] and lymphoplasmacytoid/Waldenström macroglobulinemia [LPL-WM]) and r/r to ≥ 2 prior lines of treatment were eligible. Previous treatment had to include rituximab and an alkylating agent. Copanlisib (60 mg, I.V.) was administered intermittently on days 1, 8 and 15 of a 28-day cycle. The primary efficacy endpoint was ORR as assessed per independent radiologic review (Cheson et al. 2007).


The full analysis set comprised 142 patients, of which 141 patients had indolent lymphoma (FL/MZL/SLL/LPL-WM: 104/23/8/6). ORR per histological subgroup was 58.7%/69.6%/75.0%/16.7%, respectively. ORR based on demographics were generally consistent across categories. Likewise, there were no major differences in ORR between any of the baseline disease characteristics and prior therapy subgroups with regards to ECOG PS (0 [58.8%] vs. ≥ 1 [59.7%]), longest diameter of baseline lesion (< 7cm [59.8%] vs. ≥ 7cm [59.1%]), received prior bendamustine (yes [62.7%] vs. no [56.6%]), number of prior therapies (< 4 [59.8%] vs. ≥ 4 [57.5%]), or refractoriness to last regimen (yes [60.5%] vs. no [57.1%]). Median duration of response (DOR) by tumor histology for the subgroups with ≥ 10 responders was 370 days (range 33-687) for FL patients and had not yet been reached for MZL patients (2 of 16 responders having progressed).


Objective response rates were consistently high in patients with r/r indolent B-cell lymphoma treated with copanlisib with the exception of LPL-WM patients. There were no major differences in the ORR between any of the baseline disease characteristics and prior therapy subgroups, confirming the robustness of the primary efficacy endpoint.

Clinical trial identification


Legal entity responsible for the study

Bayer AG


Bayer AG


T. Ishida: Employment: Bayer SA. L. Huang, J. Garcia-Vargas, B.H. Childs: Employment: Bayer HealthCare Pharmaceuticals Inc. M. Dreyling: Advisory boards: Bayer, Gilead Honoraria: Bayer, Gilead. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.